---
document_datetime: 2023-09-21 21:40:54
document_pages: 27
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/descovy-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: descovy-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 18.9084276
conversion_datetime: 2025-12-28 05:13:15.506682
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Descovy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1588              | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 16/02/2023                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0060/G   | was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient                                                                                                                                                                                                                                                                      | 11/11/2022   | n/a   |             | This   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|--------|
| WS/2331     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                   | 10/11/2022   |       | SmPC and PL |        |
| WS/2315/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 10/11/2022   | n/a   |             |        |
| II/0057     | Submission of the clinical study report and supporting modular summaries for study GS-US- 311-1269 'Phase 2/3, Open Label, Multi-Cohort                                                                                                                                                                                                                                                                                                                                        | 07/07/2022   | n/a   |             |        |

<div style=\"page-break-after: always\"></div>

|           | Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen' in fulfilment of the milestone for the Category 3 additional pharmacovigilance activity to address the safety concern of Long-term safety information in adolescents (missing information) as detailed in the Descovy EU Risk Management Plan (RMP). The RMP was amended as version 7 in line with this submission and to update the list of safety concerns. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |     | Switch Study to   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IG/1456   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/11/2021 | n/a |                   |
| IG/1412   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/07/2021 | n/a |                   |
| IB/0052/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/05/2021 | n/a |                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | arrangements and   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------|
| WS/2030   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update section 4.4 of the SmPC and section 2 of the PL with information regarding nephrotoxicity, in alignment with the outcome of procedure EMEA/H/C/PSUSA/00010575/201911 already approved for Vemlidy. In addition, the marketing authorisation holder has taken the opportunity to introduce minor editorial changes for Biktarvy and to align the PI of all four products to the latest QRD template (v. 10.2). C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 20/05/2021 | 13/06/2022 | SmPC and PL |                    |
| IG/1396/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/05/2021 | n/a        |             |                    |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |                       |                                                                                                                                                                                                                                                                       |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0051              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                    | 12/11/2020 | 11/02/2021 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Descovy in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10515 /202004 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                        | 29/10/2020 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| IB/0049             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                              | 08/06/2020 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| WS/1745             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                               | 28/05/2020 | 11/02/2021 | PL                    |                                                                                                                                                                                                                                                                       |
| IG/1236             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                        | 04/05/2020 | n/a        |                       |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IAIN/0047/G         | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 13/03/2020 | 23/04/2020 | SmPC, Labelling and PL |                                   |
| II/0044             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                            | 27/02/2020 | n/a        |                        |                                   |
| WS/1746             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                     | 06/02/2020 | n/a        |                        |                                   |
| PSUSA/10515 /201904 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                      | 31/10/2019 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/1125   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/06/2019   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1429   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC of Descovy, Genvoya and Odefsey with data in patients on chronic haemodialysis from the Study GS-US-292-1825; this is a Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Haemodialysis. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to remove boceprevir drug-drug interaction information in section 4.5 of the SmPC since this medicinal product has been withdrawn from the EU market, as well as to introduce some minor amendments throughout the product information of Descovy, Genvoya and Odefsey. The Package Leaflet is updated accordingly. Moreover, the Package Leaflet of Genvoya and Odefsey have been updated regarding the lactose | 26/04/2019   | 06/06/2019 | SmPC, Labelling and PL | In study GS US 292 1825, the efficacy and safety of of emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet in HIV-1 infected adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis were evaluated. There were no new safety issues identified in these patients. No clinically relevant differences in tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal disease on chronic haemodialysis as compared to those with normal renal function. Efficacy was maintained through 48 weeks but emtricitabine exposure was significantly higher than in patients with normal renal function. Although there were no new safety issues identified, the implications of increased emtricitabine exposure remain uncertain. Therefore, it is recommended that Descovy, Genvoya and Odefsey should generally be avoided but may be used in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits are considered to outweigh the potential risks. No dose adjustment is required in these patients. Based on this, sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC of Descovy, Genvoya and Odefsey have been updated accordingly. |

<div style=\"page-break-after: always\"></div>

|         | and package leaflet of medicinal products for human use'; as well as an administrative correction to the Genvoya Package Leaflet in order to add 'lurasidone' to the second list of contra-indicated drugs. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                             |            |            |                                  |                                                                                                                                                                                                                                                                                                |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1566 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC following a safety review by the MAH assessing the clinical evidence of a causal association between tenofovir alafenamide- containing products and two adverse events, angioedema and urticaria. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor linguistic amendments and editorial changes to the Odefsey and Vemlidy products information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 02/05/2019 | 23/04/2020 | SmPC, Annex II, Labelling and PL | Based on post-marketing surveillance data, there is sufficient evidence to consider that a causal association between tenofovir alafenamide-containing products and two adverse events, angioedema and urticaria, with the frequency uncommon. The Product information is updated accordingly. |
| IG/1009 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/12/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/1466/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 29/11/2018 | n/a |                                   |
| IG/1001             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/11/2018 | n/a |                                   |
| PSUSA/10515 /201804 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 31/10/2018 | n/a | PRAC Recommendation - maintenance |
| IA/0038             | B.II.b.3.a - Change in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/10/2018 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                |            |            |                     |                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|------------------------------|
| WS/1441   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH is required | 04/10/2018 | n/a        |                     | where significant assessment |
| WS/1430   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other                                                                                                                                                           | 04/10/2018 | n/a        |                     | variation                    |
| IG/0983   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                  | 13/09/2018 | 06/06/2019 | SmPC                |                              |
| IAIN/0037 | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                | 11/09/2018 | n/a        |                     |                              |
| T/0030    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                             | 25/04/2018 | 28/05/2018 | SmPC, Labelling and |                              |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            | PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| IB/0029             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/04/2018 | n/a        |      |                                   |
| PSUSA/10515 /201710 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/04/2018 | n/a        |      | PRAC Recommendation - maintenance |
| WS/1310             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the Descovy, Genvoya, Odefsey and Vemlidy SmPCs in order to include information on the drug-drug interaction with sofosbuvir/velpatasvir/voxilaprevir fixed dose combination based on the results of study GS- US0367-1657, listed as a category 3 in the Vemlidy RMP, in order to fulfil MEA 006 for Vemlidy. Study GS-US0367 is a phase I multiple dose study to evaluate the drug-drug interaction potential between sofosbuvir/velpatasvir/voxilaprevir fixed dose combination and HIV anti-retrovirals in healthy subjects. In addition, the Worksharing applicant (WSA) took the opportunity to make some small corrections to section 4.5 of the SmPC for Descovy, Genvoya, Odefsey and Vemlidy and to make corrections to the DE, ES, HU, IS, IT, LV, NO, PT, SL and SV translations for Vemlidy. | 22/03/2018 | 28/05/2018 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

|         | - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |      | C.I.4 new data    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------|
| II/0025 | Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to reflect week 48 results from study GS-US- 311-1717, listed as a category 3 study in the RMP; this is a Phase 3b, randomized, double-blind, switch study to evaluate Descovy (F/TAF) in HIV-1 infected subjects who are virologically suppressed on regimens containing abacavir/lamivudine (ABC/3TC). In addition, the Marketing authorisation holder (MAH) took the opportunity to make administrative updates and Minor Linguistic Amendments to the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to preclinical, clinical or pharmacovigilance | 18/01/2018 | 19/04/2018 | SmPC | new quality, data |
| WS/1305 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                      | 18/01/2018 | n/a        |      |                   |
| IG/0877 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/12/2017 | n/a        |      |                   |

<div style=\"page-break-after: always\"></div>

|                     | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                                                                                                                                                                                                                     |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0861             | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/11/2017 | n/a        |      |                                                                                                                                                                                                                     |
| PSUSA/10515 /201704 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26/10/2017 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                   |
| IA/0022             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/10/2017 | n/a        |      |                                                                                                                                                                                                                     |
| WS/1205             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC of Genvoya, Descovy and Odefsey in order to provide the final study report for the in vitro study AD-120-2045; this is a non-clinical study on the Effect of Xanthine Oxidase Inhibitors on Metabolism of Tenofovir alafenamide fumarate in Primary Human Hepatocytes. This study is listed in the respective Risk Management Plans as an additional pharmacovigilance activity (Category 3) (Genvoya: MEA 006; Descovy: MEA 004; Odefsey: MEA 007). | 14/09/2017 | 19/04/2018 | SmPC | Based on data from the in vitro study AD-120-2045, co administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g. febuxostat) is not expected to increase systemic exposure to tenofovir in vivo. |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/09/2017 | 19/04/2018 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IG/0799 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/07/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| WS/1136 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4, 4.8, and 5.1 of the SmPC in order to provide 48 weeks data from Study GS-US- 292-1249; a Phase 3b open-label study of the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide single-tablet regimen in HIV-1/Hepatitis B co-infected adults. The Package Leaflet is updated accordingly. In addition, the Worksharing Applicant (WSA) took the opportunity to update the list of local representatives (Lithuania, Latvia and Estonia), update section 4.5 of the SmPC with the removal of telaprevir due to the withdrawal of the marketing | 06/07/2017 | 19/04/2018 | SmPC and PL | The following existing information in the SmPC was updated to reflect the efficacy and safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) evaluated in 72 adult patients co infected with Human Immunodeficiency virus (HIV 1) and chronic hepatitis B (HBV) in the open label Study GS-US- 29201249. Tenofovir alafenamide is active against hepatitis B virus (HBV). Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to antibodies against hepatitis B e antigen (anti HBe) at Week 48. Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti HBs at Week 48. At Week 48, 92% of patients (66/72) maintained HIV 1 RNA < 50 copies/mL after switching to E/C/F/TAF. The mean change from baseline in CD4+ cell count at Week 48 was 2 |

<div style=\"page-break-after: always\"></div>

|         | authorisation in the EU and to include minor administrative changes in the SmPC and the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             | cells/mm3. Ninety two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48. Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and 3 had missing data. Of the 10 patients who were not HBV suppressed at baseline (HBV DNA  29 I U/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data. Alanine aminotransferase (ALT) normalisation was achieved in 40% (4/10) of subjects with ALT greater than upper limit of normal (ULN) at baseline. There are limited clinical data on the use of E/C/F/TAF in HIV/HBV co infected patients who are treatment nave. The safety profile of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed dose combination tablet, in patients with HIV/HBV co infection, was similar to that in patients with   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1152 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC in order to amend the study duration and percentages of subjects maintaining HIV RNA <50 copies/mL at Week 144 regarding undesirable effects and pharmacodynamic properties of Genvoya, Descovy and Odefsey following Week 144 efficacy and safety data from Study GS-US-292-0112, listed as a category 4 study in the Risk Management Plan; this is a phase 3 open-label safety study of elvitegravir/cobicistat/emtricitabine/tenofovir | 05/05/2017 | 19/04/2018 | SmPC and PL | The following existing information in the SmPC was updated to reflect the new study duration and the percentages of subjects maintaining HIV RNA <50 copies/mL at Week 144. The safety of emtricitabine and tenofovir alafenamide was evaluated through 144 weeks in an open-label clinical study (GS US 292 0112) in which 248 HIV 1 infected patients who were either treatment-nave (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment (estimated glomerular filtration rate by Cockcroft Gault method [eGFRCG]: 30 69 mL/min) received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. The safety profile in patients with mild to moderate renal impairment was similar to that in                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | alafenamide single-tablet regimen in HIV-1 positive patients with mild to moderate renal impairment. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | patients with normal renal function. At Week 144, 83.1% (197/237 patients) maintained HIV 1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10515 /201610 | Periodic Safety Update EU Single assessment - emtricitabine / tenofovir alafenamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 05/05/2017 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/1133/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Updates of sections 4.4 and 4.5 of the SmPC for the tenofovir disoproxil fumarate (TDF)-containing products (Viread, Truvada, Atripla, Stribild) which includes the results from Study GS-US-342-1167 and Study GS-US-342-1326. The Package Leaflets and Risk Management Plans for Viread (v. 22), Truvada (v.14), Atripla (v.16) and Stribild (v.11.1) have been updated accordingly. Update of section 4.5 for the tenofovir alafenamide (TAF)-containing products (Genvoya, Descovy, Odefsey) and for Eviplera, which include the results from Study GS-US-342-1167. The Risk Management Plan for Eviplera (v.13) has been updated accordingly. Administrative update of section 4.8 of the SmPC for Viread, Atripla, Eviplera and Stribild. | 21/04/2017 | 19/04/2018 | SmPC and PL | The Marketing Authorisation Holder has submitted the results from Study GS-US-342-1167 and Study GS-US- 342-1326 to update the Product Information for tenofovir disoproxil fumarate (TDF)-containing products (Viread, Truvada, Atripla, Eviplera and Stribild) and tenofovir alafenamide (TAF)-containing products (Genvoya, Descovy, Odefsey). Study GS-US-342-1167 is a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Riplivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) o Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects. The recommendation stemming from this study is that no dose adjustment of sofosbuvir/velpatasvir with Eviplera orGenvoya is warranted upon co-administration, and that Atripla should not be co-administered with sofosbuvir/velpatasvir. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study GS-US-342-1167 is a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Riplivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) o Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects. Study GS-US-342-1326, a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/GS-5816 (SOF/GS-5816) Fixed- Dose Combination (FDC) Tablet and HIV Antiretroviral Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF), Ritonavir- boosted Darunavir (DRV/r) plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Ritonavir-boosted Atazanavir (ATV/r) plus FTC/TDF, Ritonavir/boosted Lopinavir (LPV/r) plus FTC/TDF or Raltegravir plus FTC/TDF. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | Study GS-US-342-1326, a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/GS-5816 (SOF/GS-5816) Fixed-Dose Combination (FDC) Tablet and HIV Antiretroviral Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF), Ritonavir-boosted Darunavir (DRV/r) plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Ritonavir-boosted Atazanavir (ATV/r) plus FTC/TDF, Ritonavir/boosted Lopinavir (LPV/r) plus FTC/TDF or Raltegravir plus FTC/TDF. Results showed that no dose adjustment is recommended. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders. Renal function should be closely monitored.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1010   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.2 of the SmPC in order to provide the final results from Study GS-US-320-1615 'A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects with Normal Hepatic Function and Subjects with Severe Hepatic Impairment'. In addition, the Worksharing applicant (WSA) took the opportunity to update section 4.2 of the SmPC for Descovy. The information from the CSR for Study GS-US-320- 1615 does not lead to the addition or deletion of a safety concern in the corresponding RMPs. The requested worksharing procedure proposed amendments to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 23/02/2017   | 29/03/2017   | SmPC   | Results from Study GS-US-320-1615 showed that no clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were observed in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013   | Update of sections 4.8 and 5.1 of the Summary of Product Characteristics (SmPC) for Descovy with adverse reactions, virological outcomes and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/02/2017   | 29/03/2017   | SmPC   | In a study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate (Truvada; FTC/TDF) to Descovy while maintaining the third                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| measures of bone mineral density based on 96 week data from Study GS-US-311-1089; this is a Phase 3, randomized,double-blind, multicenter, active- controlled study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | data   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1062   | This was an application for a variation following a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/01/2017   | 29/03/2017   | SmPC   | Assessment of adverse reactions is based on safety data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           | worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC for Genvoya, Descovy and Odefsey in order to provide long-term efficacy and safety data for HIV-infected, antiretroviral therapy-naive adults with results through 144 weeks of treatment with Genvoya from studies GS-US- 292-0104 and GS-US- 292-0111; two Phase III, randomized, double-blind, multicenter, active-controlled studies to evaluate the safety and efficacy of Genvoya vs Stribild. In addition, the Worksharing applicant (WSA) took the opportunity to make minor administrative corrections to sections 4.4 and 5.1 of the SmPC for Genvoya and Descovy and linguistic amendments in Slovakian, Swedish, Polish, Latvian, Czech and Portuguese. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data |              |              |        | from across all Phase 2 and 3 studies in which 2,396 patients received Genvoya. The most frequently reported adverse reactions in clinical studies through 144 weeks were nausea (11%), diarrhoea (7%), and headache (6%) (pooled data from Phase 3 clinical studies GS-US-292-0104 and GS-US-292-0111 in 866 treatment-nave adult patients receiving Genvoya). Cobicistat increases serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. In clinical studies of Genvoya, increases in serum creatinine occurred by Week 2 of treatment and remained stable through 144 weeks. In treatment-nave patients, a mean change from baseline of 0.04  0.12 mg/dL (3.5  10.6 mol/L) was observed after 144 weeks of treatment. Mean increases from baseline in the Genvoya group were smaller than in the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 144 (difference -0.04, p < 0.001). In studies in treatment nave patients, increases from baseline were observed in both treatment groups for the fasting lipid parameters total cholesterol, direct low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, and triglycerides at Week 144. The median increase from baseline for those parameters was greater in the Genvoya group compared with the E/C/F/TDF group at Week 144 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL and HDL cholesterol, and triglycerides). The median (Q1, Q3) |

<div style=\"page-break-after: always\"></div>

| change from baseline in total cholesterol to HDL cholesterol ratio at Week 144 was 0.2 ( 0.3, 0.7) in the Genvoya group and 0.1 ( 0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups).  In a pooled analysis, genotyping was performed on plasma HIV 1 isolates from antiretroviral-nave patients receiving Genvoya in Phase 3 studies GS US 292 0104 and GS US 292 0111 with HIV 1 RNA  400 copies/mL at confirmed virologic failure, Week 144, or time of early study drug discontinuation.  Up to Week 144, the development of one or more primary elvitegravir, emtricitabine, or tenofovir alafenamide resistance-associated mutations was observed in HIV 1 isolates from 12 of 22 patients with evaluable genotypic data from paired baseline and Genvoya treatment-failure isolates (12 of 866 patients [1.4%]) compared with 12 of 20 treatment failure isolates from patients with evaluable genotypic data in the E/C/F/TDF treatment group (12 of 867 patients [1.4%]).  Of the HIV 1 isolates from 12 patients with resistance development in the Genvoya group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) and N155H (n = 2) in integrase.  Of the HIV 1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 9), K65R/N (n = 4), and L210W (n = 1) in RT and E92Q/V (n = 4), and Q148R (n = 2), and N155H/S (n = 3) in integrase. Most HIV 1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir developed resistance mutations to both emtricitabine and elvitegravir.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| In phenotypic analyses of patients in the final resistance analysis population, 7 of 22 patients (32%) had HIV 1 isolates with reduced susceptibility to elvitegravir in the Genvoya group compared with HIV 1 isolates from 7 of 20 patients (35%) in the E/C/F/TDF group, HIV 1 isolates from 8 patients (36%) had reduced susceptibility to emtricitabine in the Genvoya group compared with HIV 1 isolates from 7 patients (35%) in the E/C/F/TDF group. One patient in the Genvoya group (1 of 22 [4.5%]) and 2 patients in the E/C/F/TDF group (2 of 20 [10%]) had reduced susceptibility to tenofovir. Genvoya met the non inferiority criteria demonstrated statistical superiority in achieving HIV 1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144. The difference in percentage was 4.2% (95% CI: 0.6% to 7.8%). Changes in measures of bone mineral density In studies in treatment nave patients, Genvoya was associated with smaller reductions in bone mineral density (BMD) compared to E/C/F/TDF as measured by DXA analysis of hip (mean change: -0.8% vs -3.4%, p < 0.001) and lumbar spine (mean chan ge: -0.9% vs -3.0%, p < 0.001) after 144 weeks of treatment. Improvements in BMD were noted at 96 weeks after switching to Genvoya from a TDF-containing regimen compared to maintaining the TDF-containing regimen.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |      | associated with a lower impact on renal safety parameters (as measured after 144 weeks treatment by estimated glomerular filtration rate by Cockcroft Gault method, and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF (see also section 4.4). Through 144 weeks of treatment, no subject discontinued Genvoya due to a treatment emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1034 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC for Genvoya, Descovy and Odefsey with new information regarding interactions with oral contraceptives norgestimate and ethinyl estradiol, from the final clinical study report (CSR) for Study GS-US-311-1790: \"A Phase 1, Randomized, Open Label, Drug Interaction Study Evaluating the Effect of Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Tablet or GS- 9883 on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol\". C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2016 | 29/03/2017 | SmPC | In section 4.5 of the SmPC, the following oral contraceptives have been listed as having an interaction with the individual components of Descovy, Genvoya and Odefsey: Norgestimate (0.180/0.215/0.250 mg once daily), ethinylestradiol (0.025 mg once daily). The recommendation concerning their co-administration with Descovy is that no dose adjustment of norgestimate/ethinylestradiol is required. Descovy should be dosed according to the concomitant antiretroviral in line with section 4.2 of the SmPC. The recommendation concerning their co-administration with Odefsey is that no dose adjustment is required. The recommendation concerning the co-administration of a hormonal contraceptive with Genvoya is that caution should be exercised. The hormonal contraceptive should contain at least 30 g ethinylestradiol and contain norgestimate as the progestagen or patients should use an alternative reliable method of contraception. The long-term effects of substantial increases in progesterone exposure are unknown. The effect of co administration of Genvoya with oral contraceptives containing progestagens other than norgestimate is not |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        | known and therefore should be avoided.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0745 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                             | 28/11/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0010 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                           | 28/11/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0009 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                   | 26/10/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IG/0725 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                           | 21/10/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| WS/0978 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.8 and 5.1 of the SmPC for Genvoya, Descovy and Odefsey in order to update the safety information of virologically suppressed patients with mild to moderate renal impairment with Week 96 efficacy and safety data from Study GS-US- 292-0112 \"A Phase 3 Open-label Safety Study of | 15/09/2016 | 29/03/2017 | SmPC, Labelling and PL | The safety of emtricitabine and tenofovir alafenamide was evaluated through 96 weeks in an open-label clinical study (GS US 292 0112) in which 248 HIV 1 infected patients who were either treatment-nave (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment (estimated glomerular filtration rate by Cockcroft Gault method [eGFRCG]: 30 69 mL/min) received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. |

<div style=\"page-break-after: always\"></div>

| Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment\". The Package Leaflet and Labelling are updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to update section 4.4 of the SmPC for Genvoya and section 2 of the Package Leaflet with the MITOC class labelling text (EMEA/H/C/xxxx/WS/0792) and to bring the PI for Genvoya and Descovy in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to or pharmacovigilance   | new quality, preclinical, clinical data   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|

<div style=\"page-break-after: always\"></div>

| II/0002   | Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to provide additional efficacy and safety data for antiretroviral therapy-naive adults from Studies GS-US-292-0104 and GS-US-292-0111 through 96 weeks of treatment. The Package Leaflet is updated accordingly. The MAH has also taken the opportunity to update the DDI table in Section 4.5 by adding a new footnote and removing another to increase clarity. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 15/09/2016   | 29/03/2017   | SmPC and PL   | The MAH has updated section 4.2 of the SmPC to note that there are limited data available regarding the use of Descovy (DVY) in patients with estimated CrCl < 30 mL/min; previously it stated there was no data. The summary of the safety profile in section 4.8 and the pharmacodynamic properties in section 5.1 were further updated to reflect 96 weeks data from clinical studies of treatment-nave adult patients with Genvoya (GEN). Data from GEN clinical studies presented through 96 weeks of treatment in ART-naive adults in the current submission are consistent with the findings in the original submission. At Week 96, GEN was noninferior to Stribild. The efficacy of GEN in subgroup analyses revealed no meaningful differences in virologic success. The frequency of resistance development in ART-naive subjects taking GEN was acceptably low and comparable to that of the STB group through 96 weeks of treatment. Treatment with GEN continued to be well tolerated, as demonstrated by the incidence of SAEs considered related to study drug, or study drug discontinuation due to AEs. No new ADRs were identified. Based on the demonstrated bioequivalence between FTC/TAF from Genvoya and Descovy these results demonstrate that DVY is beneficial as a chronic treatment for ART-naive subjects.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0708   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/08/2016   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IG/0711   | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 27/07/2016   | n/a   |                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------|
| IB/0001/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 22/06/2016   | n/a   | control/testing takes place |